Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study

Xin Fan†, Yanqing Liu†, Zhigang Liang§, Shanshan Wang§, Jing Yang§ and Aihua Wu‡*

1Department of Dermatology, Ningbo First Hospital, Ningbo, China, 2Department of Laboratory Medicine, Ningbo First Hospital, Ningbo, China, 3Department of Thoracic Surgery, Ningbo First Hospital, Ningbo, China, 4Department of Respiratory and Critical Care, Ningbo First Hospital, Ningbo, China

Background: The diagnostic value of tumor markers in pleural effusion (PE) and serum for malignant pleural effusion (MPE) is still in debate. This study aimed to evaluate the diagnostic value of six tumor markers in PE, serum, and the corresponding PE/serum (PE/S) ratio in distinguishing MPE from benign pleural effusion (BPE).

Methods: A total of 1,230 patients with PE (452 MPEs and 778 BPEs) were retrospectively included in the study. PE and serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), cytokeratin 19 fragment (CYFRA 21-1), and neuron-specific enolase (NSE) were measured. The area under the curve (AUC) was used to assess the single and combined diagnostic values of the six tumor markers for MPE.

Results: The levels of the six tumor markers in PE, serum, and PE/S were significantly higher in MPE than that in BPE, except for serum CA125. PE CEA showed the highest AUC [0.890 (0.871–0.907)] at a cut-off value of 3.7 ng/ml compared to any single tumor marker using receiver operating characteristic (ROC) analysis. The specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) of PE CEA were 74.1%, 95.5%, 90.5%, 86.4%, 16.47, and 0.27, respectively. The combination of PE CEA and serum CYFRA21-1 showed the best diagnostic performance with an AUC of 0.934 (sensitivity, 79.9%; specificity, 95.7%, PPV, 90.5; PLR, 17.35) among all two or three combinations. Besides, serum CYFRA21-1 was the best diagnostic tumor marker in distinguishing cytology-negative MPE from BPE at a cut-off value of 3.0 ng/ml.

Conclusion: PE CEA was the best diagnostic tumor marker in distinguishing MPE from BPE. Serum CYFRA21-1 was the best diagnostic tumor marker in distinguishing cytology-negative MPE from BPE. The combination of PE CEA and serum CYFRA21-1 could increase the diagnostic performance in distinguishing MPE from BPE and cytology-negative MPE from BPE.

Keywords: diagnostic performance, malignant pleural effusion, tumor markers, carcinoembryonic antigen, cytokeratin 19 fragment, area under the curve
INTRODUCTION

Pleural effusion (PE) is a clinically common complication in patients with physical trauma or systemic disorders, such as cancer, inflammation, and infection [1, 2]. A malignant tumor is one of the main causes leading to PE, and more than 90% of malignant pleural effusion (MPE) is due to metastatic disease, which might endanger the patient’s survival [3]. Therefore, elucidating the etiologies of PE is critically important for involving treatment options and prognoses of PE patients, especially to differentiate MPE from benign pleural effusion (BPE). The negative rate of conventional PE cytology in malignant PEs can be as high as 40%, and even higher in PEs of squamous-cell lung carcinomas and mesotheliomas [4, 5]. The cytological examination is influenced not only by tumor types, but the number of analyzed specimens, cytologist’s experience, and the volume of pleural fluid processed [1, 3]. In addition, under some circumstances, non-specific inflammatory PE derived from lung tumor development, lymphatic obstruction, and/or immune-mediated inflammation might account for the failure of a cytology examination. Although thoracoscopy and/or thoracotomy present high diagnostic sensitivity for MPE, the safety and need for a confirmatory pleural biopsy in patients with suspected MPE or cytology-negative MPE in studies vary widely [6, 7].

On this occasion, tumor markers have been reported to aid the diagnosis of malignancy, such as carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 125 (CA125), and cytokeratin 19 fragment (CYFRA 21-1) [8]. Besides, tumor markers in PE have been considered to be less invasive for differentiating MPE from BPE. Although those tumor markers have been extensively assessed for distinguishing between MPE and BPE in numerous studies, the inconsistent cut-offs, sensitivities, and specificities of those tumor markers for definitive diagnosis of MPE have raised controversies [8, 9].

Therefore, the present study aimed to evaluate six tumor markers (CEA, CA15-3, CA125, CA19-9, CYFRA21-1, and NSE) in PE, serum, and the corresponding PE/serum (PE/S) ratio in distinguishing MPE from BPE either singly or in combination. We also assessed the diagnostic value of the aforementioned six tumor markers in distinguishing cytology-negative MPE from BPE either singly or in combination.

MATERIALS AND METHODS

Patients

Pleural effusion was examined by thorough anamnesis, physical examination (lung percussion and auscultation), X-ray, or chest CT, and was confirmed by thoracentesis. A total of 1,230 patients with PE admitted to the Department of Thoracic Surgery and Respiratory and Critical Care of Ningbo First Hospital from 1 January 2014 to 1 March 2021 were enrolled and analyzed retrospectively. The diagnosis of MPE or BPE was made based on the combination of cytology, thoracoscopy, imagological examination, and at least a 6-month follow-up. The cytology examination was performed on stained slides of fresh PE samples by two pathologists. Based on cytological results, MPE was classified into three categories, namely positive cytology (n = 262), suspected cytology (n = 60), and negative cytology (n = 130). The causes of MPE (n = 452) and BPE (n = 778) in the 1,230 patients are shown in Table 1. As shown in Table 1, lung cancer (78.8%), breast cancer (3.3%), and gastric cancer (2.6%) were the leading causes of MPE. Tuberculosis (49.5%), parapneumonic (19.4%), and congestive heart failure (10%) were the leading causes of BPE. Besides, PEs from patients with a history of definite malignant tumors was also considered to be malignant if other diseases were excluded. The exclusion criteria were as follows: 1) younger than 18 years old; 2) pregnant women; and 3) incomplete data. Besides, patients initially diagnosed with BPE were excluded if they developed any tumor during follow-up periods. Mesothelioma and hematological malignancy were also excluded for not frequently elevated CEA when PE was caused these malignancies. The clinicopathological characteristics, including age, gender, smoking history, level of six tumor markers (CEA, CA15-3, CA125, CA19-9, CYFRA 21-1, and NSE) in PE and serum, and cytological data were obtained from the electronic medical record system for patients. The present study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Ningbo First Hospital (No. 2021RS133).

PE and Serum Tumor Markers Analysis

PE samples were collected from all patients by standard thoracentesis within 24 h of admission. Fasting peripheral blood samples (4.0 ml) were drawn from all patients before treatment. PE and blood samples were transported to the Department of Clinical Laboratory Medicine within 1 h. CEA,
CA15-3, CA125, and CA19-9 were detected by a chemiluminescence method (Cobas e602, Roche Diagnostics, Germany), and CYFRA21-1 and NSE were detected by an electrochemical luminescence method (Cobas e602, Roche Diagnostics, Germany) with commercial assay kits according to the manufacturer’s instructions. The reference interval of the aforementioned tumor markers in serum was recommended as follows: 5 ng/ml for CEA, 14 U/ml for CA15-3, 35 U/ml for CA125, 25.0 ng/ml for CA19-9, 3.3 ng/ml for CYFRA21-1, and 16.3 ng/ml for NSE.

### Statistical Analysis

All statistical analyses were performed using MedCalc version 18.0 (MedCalc Software Ltd., Ostend, Belgium) and R Studio software version 4.0.5 (http://www.r-project.org) with the OptimalCutpoints package. A two-tailed $p < 0.05$ was considered to be significantly different.

Categorical variables were determined by the Chi-squared ($\chi^2$) test. Continuous variables were presented as mean ± standard deviation (SD). Continuous variables were determined by the nonparametric Mann-Whitney U test. The optimal cut-off value, area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) of each tumor marker and the corresponding PE/serum ratio were calculated by R Studio software. Besides, the better tumor markers with good diagnostic value were defined as an AUC greater than 0.75. The receiver operating characteristic (ROC) curves were calculated by MedCalc software.

### RESULTS

The Levels of Six Tumor Markers and Their Corresponding PE/S Ratios in Total MPE, Cytology-Negative MPE, and BPE Patients

The basic characteristics and six tumor marker levels in PE, serum, and PE/S among total MPE, cytology-negative MPE, and BPE are presented in Table 2. Among 1,230 patients, 452 patients had MPE (262 men, 190 women) and 778 had BPE (519 men, 259 women). Besides, 130 patients with MPE were cytology-negative. The average age of patients who had total MPE and cytology-negative MPE was older than that in BPE patients (67.8 years and 67.3 years versus 56.1 years, $p < 0.001$, Table 2). The gender between total MPE and BPE was statistically different ($p = 0.003$, Table 2), while that between cytology-negative MPE and BPE was not ($p = 0.688$, Table 2). No statistical difference was observed in

### Table 2

| Variables                  | BPE (n = 778) | Total MPE (n = 452) | Cytology-negative MPE (n = 130) | $p^a$ Value | $p^b$ Value |
|----------------------------|---------------|---------------------|--------------------------------|-------------|-------------|
| Age (years)                | 56.1 ± 20.7   | 67.8 ± 13.0         | 67.3 ± 12.8                    | <0.001      | <0.001      |
| Gender (n, %)              |               |                     |                                |             |             |
| Male                       | 519 (66.7%)   | 262 (58.0%)         | 84 (64.6%)                     | 0.003       | 0.688       |
| Female                     | 259 (33.3%)   | 190 (42.0%)         | 46 (35.4%)                     |             |             |
| Smoking status (n, %)      |               |                     |                                |             |             |
| Non-smoker                 | 494 (63.5%)   | 278 (61.5%)         | 77 (59.2%)                     | 0.501       | 0.378       |
| C/F smoker                 | 284 (36.5%)   | 174 (38.5%)         | 53 (40.8%)                     |             |             |
| PE CEA (ng/ml)             | 1.7 ± 5.6     | 280.9 ± 395.9       | 81.0 ± 227.0                   | <0.001      | <0.001      |
| Serum CEA (ng/ml)          | 1.8 ± 1.2     | 70.1 ± 183.6        | 26.9 ± 108.9                   | <0.001      | <0.001      |
| PE/S CEA                   | 1.0 ± 3.5     | 21.1 ± 76.2         | 5.3 ± 12.9                     | <0.001      | <0.001      |
| PE CA15-3 (U/ml)           | 7.4 ± 10.3    | 96.5 ± 174.3        | 30.9 ± 98.9                    | <0.001      | 0.080       |
| Serum CA15-3 (U/ml)        | 8.9 ± 9.2     | 35.4 ± 77.7         | 27.6 ± 85.3                    | <0.001      | 0.001       |
| PE/S CA15-3                | 0.9 ± 0.9     | 3.6 ± 7.3           | 1.2 ± 2.0                      | <0.001      | 0.190       |
| PE CA125 (U/ml)            | 1,310.3 ± 1,168.2 | 2,148.2 ± 1,562.3  | 1,549.2 ± 1,303.9              | <0.001      | 0.091       |
| Serum CA125 (U/ml)         | 133.6 ± 141.9 | 258.7 ± 605.0       | 164.8 ± 342.2                  | 0.033       | 0.794       |
| PE/CA125                   | 21.4 ± 60.9   | 29.7 ± 56.1         | 22.5 ± 51.0                    | <0.001      | 0.586       |
| PE CA19-9 (ng/ml)          | 9.9 ± 91.9    | 298.6 ± 616.5       | 136.6 ± 424.8                  | <0.001      | <0.001      |
| Serum CA19-9 (ng/ml)       | 12.6 ± 50.8   | 102.2 ± 331.5       | 55.1 ± 213.9                   | <0.001      | <0.001      |
| PE/CA19-9                  | 0.7 ± 4.1     | 11.6 ± 47.8         | 5.9 ± 31.8                     | <0.001      | <0.001      |
| PE CYFRA21-1 (ng/ml)       | 36.2 ± 48.1   | 161.3 ± 177.7       | 89.6 ± 120.7                   | <0.001      | <0.001      |
| Serum CYFRA21-1 (ng/ml)    | 2.3 ± 1.9     | 11.0 ± 27.9         | 8.4 ± 14.2                     | <0.001      | <0.001      |
| PE/S CYFRA21-1             | 23.3 ± 38.0   | 29.6 ± 45.2         | 21.2 ± 39.4                    | 0.120       | 0.038       |
| PE NSE (ng/ml)             | 15.2 ± 39.2   | 33.1 ± 60.8         | 16.4 ± 32.0                    | <0.001      | 0.912       |
| Serum NSE (ng/ml)          | 12.9 ± 8.1    | 20.8 ± 30.0         | 17.8 ± 16.3                    | <0.001      | <0.001      |
| PE/S NSE                   | 1.3 ± 3.0     | 1.9 ± 3.5           | 1.1 ± 2.4                      | <0.001      | 0.035       |

PE, pleural effusion; MPE, malignant pleural effusion; BPE, benign pleural effusion; C/F, current/former; CEA, carcinoembryonic antigen; PE/S, pleural effusion/serum; CA15-3, carbohydrate antigen 15-3; CA125, carbohydrate antigen 125; CA19-9, carbohydrate antigen 19-9; CYFRA21-1, cytokeratin 19 fragment; NSE, neuron-specific enolase.

Data were presented as mean ± standard deviation (SD) or number (percentage). $p < 0.05$ was considered to be statistically significant.

$^a$Comparisons were performed between BPE group and total MPE group using Mann-Whitney U test and Chi-squared ($\chi^2$) test.

$^b$Comparisons were performed between BPE group and cytology-negative MPE group using Mann-Whitney U test and Chi-squared ($\chi^2$) test.
TABLE 3 | Diagnostic performance of six tumor markers in PE, serum and PE/S for total MPE.

| Variables                  | Cut-off | AUC (95% CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | PLR (%) | NLR (%) |
|----------------------------|---------|--------------|----------------|----------------|---------|---------|---------|---------|
| PE CEA (ng/ml)             | 3.7     | 0.890 (0.871–0.907) | 74.1            | 95.5            | 90.5    | 86.4    | 16.47   | 0.27    |
| Serum CEA (ng/ml)          | 3.6     | 0.834 (0.808–0.859) | 64.4            | 92.2            | 82.7    | 81.7    | 3.76    | 0.60    |
| PE/S CEA                   | 1.5     | 0.811 (0.762–0.840) | 63.7            | 94.5            | 87.0    | 81.8    | 11.53   | 0.38    |
| PE CA15-3 (U/ml)           | 22.8    | 0.743 (0.712–0.775) | 49.6            | 96.9            | 90.3    | 76.8    | 16.06   | 0.52    |
| Serum CA15-3 (U/ml)        | 13.6    | 0.711 (0.680–0.742) | 47.8            | 87.3            | 86.6    | 74.2    | 3.76    | 0.60    |
| PE/S CA15-3               | 1.5     | 0.674 (0.640–0.708) | 45.8            | 89.1            | 70.9    | 73.9    | 4.19    | 0.61    |
| PE CA125 (U/ml)            | 2056.7  | 0.662 (0.631–0.694) | 42.7            | 81.4            | 57.1    | 71.0    | 2.29    | 0.70    |
| Serum CA125 (U/ml)         | 243.3   | 0.536 (0.503–0.570) | 21.5            | 86.1            | 47.3    | 65.4    | 1.55    | 0.91    |
| PE/S CA125                 | 11.3    | 0.588 (0.556–0.621) | 60.2            | 55.4            | 43.9    | 70.5    | 1.35    | 0.72    |
| PE CA19-9 (ng/ml)          | 9.2     | 0.758 (0.727–0.789) | 53.3            | 92.3            | 80.1    | 77.3    | 6.91    | 0.51    |
| Serum CA19-9 (ng/ml)       | 25.0    | 0.653 (0.620–0.688) | 31.4            | 94.0            | 75.1    | 70.2    | 5.20    | 0.73    |
| PE/S CA19-9                | 0.8     | 0.720 (0.688–0.753) | 56.2            | 87.9            | 73.0    | 77.6    | 4.65    | 0.50    |
| PE CYFRA21-1 (ng/ml)       | 59.2    | 0.764 (0.735–0.795) | 57.3            | 86.0            | 70.4    | 77.6    | 4.09    | 0.50    |
| Serum CYFRA21-1            | 3.0     | 0.852 (0.830–0.874) | 75.9            | 79.0            | 67.8    | 84.9    | 3.82    | 0.31    |
| PE/S CYFRA21-1 (ng/ml)     | 53.5    | 0.527 (0.493–0.560) | 16.6            | 90.7            | 51.0    | 65.2    | 1.79    | 0.92    |
| PE NSE (ng/ml)             | 16.5    | 0.648 (0.616–0.680) | 40.7            | 81.6            | 56.3    | 70.3    | 2.21    | 0.73    |
| Serum NSE (ng/ml)          | 12.5    | 0.681 (0.650–0.711) | 66.4            | 61.1            | 49.8    | 75.8    | 1.70    | 0.55    |
| PE/S NSE                  | 0.9     | 0.580 (0.547–0.613) | 45.4            | 67.6            | 44.9    | 68.0    | 1.40    | 0.81    |

PE, pleural effusion; PE/S, pleural effusion/serum; CEA, carcinoembryonic antigen; CA15-3, carbohydrate antigen 15-3; CA125, carbohydrate antigen 125; CA19-9, carbohydrate antigen 19-9; CYFRA21-1, cytokeratin 19 fragment; NSE, neuron-specific enolase; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio.

Area under the curve (AUC) was presented as percentage with corresponding 95% confidence intervals (95% CI). The bold values mean the variables with an AUC > 0.75.

The Diagnostic Performance of Tumor Markers for Total Malignant Pleural Effusion

The levels of CEA, CA15-3, CA125, CA19-9, CYFRA21-1, and NSE in PE, serum, and PE/S were all significantly higher in MPE patients than those in BPE patients except for PE/S CYFRA21-1 (p = 0.120, Table 2). However, the levels of CEA, CA19-9, and CYFRA21-1 in PE, serum, and PE/S were all significantly different between cytology-negative MPE and BPE (Table 2).

The Diagnostic Performance of Tumor Markers in Combination for Total Malignant Pleural Effusion

We also assessed the diagnostic performance of different tumor markers in combination in distinguishing total MPE from BPE. Indicators with AUC greater than 0.75 were used to confirm diagnosis. Since PE CEA had the largest AUC, other indicators were used for joint diagnosis with PE CEA. As shown in Table 4, the combination of PE CEA and serum CEA showed the highest specificity (97.7%), PPV (94.7%), and PLR (30.6) among all combinations, however, the AUC [0.888 (0.869–0.905)], sensitivity (70.8%), and NPV (85.2%) of PE CEA and serum CEA were relatively lower (Table 4). Considering all combinations of indicators, PE CEA and serum CYFRA 21-1 showed the best diagnostic performance with the highest AUC of 0.934 (0.919–0.947) compared with other combinations (Figure 1; Table 4). The sensitivity, specificity, PPV, NPV, PLR, and NLR of PE CEA and serum CYFRA 21-1 were 79.9%, 95.7%, 90.5%, 89.0%, 17.35, and 0.21, respectively (Table 4).

The Diagnostic Performance of Tumor Markers for Cytology-Negative Malignant Pleural Effusion

The cut-offs and AUCs of effective tumor markers for diagnosing cytology-negative MPE were as follows: 2.4 ng/ml [AUC, 0.769 (0.740–0.796)] for PE CEA and 3.0 ng/ml (AUC, 0.789 (0.761–0.815)) for serum CYFRA21-1 (Table 5). The combination of serum CYFRA21-1 and PE CEA showed the best diagnostic value in distinguishing cytology-negative MPE from BPE with an AUC of 0.834 (0.808–0.858), higher sensitivity
TABLE 4 | The combinations of CEA, CA19-9, and CYFRA21-1 in PE, serum and PE/S for differentiating total MPE from BPE.

| Tumor markers | AUC (95% CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | PLR   | NLR   |
|---------------|-------------|----------------|----------------|---------|---------|-------|-------|
| PE CEA (ng/ml)| 0.890 (0.871–0.907) | 70.4 | 95.5 | 90.5 | 86.4 | 16.47 | 0.27 |
| PE CEA + PE CA19-9 | 0.895 (0.877–0.912) | 74.8 | 95.2 | 90.1 | 86.7 | 15.72 | 0.26 |
| PE CEA + PE CYFRA21-1 | 0.902 (0.884–0.918) | 77.2 | 92.4 | 85.5 | 87.5 | 10.18 | 0.25 |
| PE CEA + serum CEA | 0.888 (0.869–0.905) | 70.8 | 97.7 | 94.7 | 85.2 | 30.60 | 0.30 |
| PE CEA + PE/S CEA | 0.896 (0.877–0.915) | 72.4 | 96.0 | 91.3 | 85.7 | 18.16 | 0.29 |
| PE CEA + serum CYFRA21-1 | 0.934 (0.919–0.947) | 79.9 | 95.7 | 90.5 | 89.0 | 17.35 | 0.21 |
| PE CEA + serum CYFRA21-1+PE CA19-9 | 0.932 (0.917–0.946) | 81.0 | 93.2 | 87.4 | 89.4 | 11.89 | 0.20 |
| PE CEA + serum CYFRA21-1+PE CYFRA21-1 | 0.933 (0.920–0.946) | 81.4 | 94.1 | 88.9 | 89.7 | 13.77 | 0.20 |
| PE CEA + serum CYFRA21-1+PE/S CEA | 0.933 (0.920–0.946) | 81.4 | 94.1 | 88.9 | 89.7 | 13.77 | 0.20 |
| PE CEA + serum CYFRA21-1+PE CA19-9 | 0.934 (0.919–0.948) | 80.1 | 95.0 | 90.3 | 89.1 | 15.98 | 0.21 |

PE, pleural effusion; PE/S, pleural effusion/serum; MPE, malignant pleural effusion; AUC, area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CYFRA21-1, cytokeratin 19 fragment. The bold values mean the single tumor marker or combinations of tumor markers with the largest AUC.

TABLE 5 | Diagnostic performance of PE CEA and serum CYFRA21-1 for cytology-negative MPE.

| Variables | Cut-off | AUC (95% CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | PLR   | NLR   |
|-----------|---------|-------------|----------------|----------------|---------|---------|-------|-------|
| PE CEA (ng/ml) | 2.4 | 0.769 (0.740–0.796) | 56.2 | 88.2 | 44.2 | 92.3 | 4.75 | 0.50 |
| serum CYFRA21-1 (ng/ml) | 3.0 | 0.789 (0.761–0.815) | 63.1 | 79.1 | 33.5 | 92.8 | 3.01 | 0.47 |
| PE CEA + serum CYFRA21-1 | 0.834 (0.808–0.858) | 67.7 | 91.0 | 61.5 | 93.0 | 9.55 | 0.45 |

PE, pleural effusion; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin 19 fragment; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio. Area under the curve (AUC) was presented as percentage with corresponding 95% confidence intervals (95% CI).

DISCUSSION

In our study, we compared the levels of PE, serum, and PE/S of CEA, CA15-3, CA125, CA19-9, CYFRA 21-1, and NSE to determine the best diagnostic tumor marker for MPE. Our results indicated that PE CEA was the best indicator to diagnose MPE with a cut-off value of 3.7 ng/ml (AUC, 0.890 (0.871–0.907)). PE CEA at 3.7 ng/ml showed higher sensitivity, specificity, PPV, and NPV for MPE when compared to another single indicator in PE, serum, and PE/S. Our study is in accordance with other previous studies [8, 9]. Huang et al. indicated that PE CEA provided better diagnostic performance in discriminating lung adenocarcinoma-associated MPE (LAC-MPE) from BPE than PE HER2/neu (human epidermal growth...
factor receptor 2/neutrophil) and PE CYFRA21-1 [10]. Similarly, another study assessing the best tumor marker for differentiating LAC-MPE from BPE obtained the same results about PE CEA [11]. Besides, Feng et al. showed that PE CEA exhibited the best diagnostic performance for differentiating LAC-MPE from BPE with an AUC of 0.95 as well as high sensitivity (87.65%) and specificity (93.75%) compared with PE CYFRA21-1 and CA19-9 [12]. Recently, a similar study from China also showed that PE CEA was the best effective indicator for diagnosing lung cancer-associated MPE among the five tumor markers (CEA, CYFRA 21-1, SCC-Ag, CA125, and NSE) at a cut-off value of 5.23 ng/ml [13]. Results showed the cut-off values, sensitivities, and specificities of PE CEA for diagnosis of MPE were widely inconsistent, probably due to different detection methods, sample sizes, and types of included cancers. Besides, several studies showed that PE CEA had dramatically low sensitivities, probably due to cases of mesothelioma and hematological tumor origin [14-17]. CEA was not increased when PE was derived from mesothelioma, lymphoma, and leukemia. In addition, studies involving only lung cancer have higher sensitivity and AUC than studies involving various cancers, which might also contribute to the inconsistencies of PE CEA [7, 15, 18-22].

CEA, a glycoprotein component of the glycocalyx, is the earliest fetal embryo antigen involved in cell adhesion. It is usually generated during fetal development, but does not appear in the peripheral blood of healthy individuals [23, 24]. Currently, serum CEA is the most used biomarker for the diagnosis and prognosis of several malignant diseases, such as lung cancer and colorectal cancer. However, PE CEA has been proven to be a more effective indicator for the diagnosis of MPE than serum CEA in previous studies [9-13, 19]. The potential mechanism was that the tumor cells metastasize to the pleural cavity by the direct invasion of the pleura or blood [25]. Therefore, the invaded tumor cells directly secreted tumor markers into the pleural cavity or the blood, which were diluted [26]. Moreover, tumor cells might block lymphatic drainage, reducing tumor markers in the blood. Therefore, tumor markers were concentrated in the pleural cavity [27].

Though PE CEA showed a good diagnostic value in distinguishing MPE from BPE, a combination of multiple tumor markers to diagnose MPE might be more valuable in clinical practice. Several studies have recommended that the diagnostic value of combinations of two or more tumor markers was greater than any single tumor marker for diagnosing MPE [8, 9, 12]. In a meta-analysis, the authors explored the diagnostic accuracies of combinations of several tumor markers (CEA, CA125, CA15-3, CA19-9, and CYFRA 21-1) for MPE [9]. The results showed that the combination of PE CEA plus CA 15-3 and PE CEA plus CA 19-9 highly indicated MPE, however, the sensitivity of these combinations was quite poor [9]. In addition, the aforementioned three studies suggested that the combination of CEA and CYFRA 21-1 exhibited a higher diagnostic performance than any single index and other combinations [10, 12, 28]. Our results were in accordance with previously reported studies [10, 12, 28]. CYFRA21-1, a fragment of cytokeratin 19 (CK19), is a common marker for epithelial malignant origin, which reflects ongoing cell activity. Increased protease activity of caspase 3 in neoplastic-transformed epithelial cells degrades CK19, which releases the fragment into the peripheral circulation. Hence, increased CYFRA 21-1 is a tumor marker reflecting the occurrence of epithelial neoplasms [29]. In the present study, the AUCs of PE CYFRA21-1 and serum CYFRA21-1 were 0.764 and 0.852, respectively. However, the sensitivity, specificity, PPV, and PLR were relatively poor.

Therefore, we used multiple indicators for joint diagnosis of MPE. In our study, the combination of PE CEA and serum CYFRA21-1 showed the highest AUC (0.934, 95% CI (0.919-0.947)) with 79.9% sensitivity and 95.7% specificity when compared with any other combinations of indicators. Besides, the PPV of the combination was 90.5%, which indicated the likelihood of developing MPE in the patients. PLR and NLR integrated advantages of sensitivity, specificity, PPV, and NPV for disease diagnosis, which were not affected by the incidence of disease. Therefore, they were relatively independent, clinically significant indexes of diagnostic test evaluation. When PLR > 10 or NLR < 0.1, the likelihood of diagnosis or exclusion of disease was significantly increased. The PLR of PE CEA and serum CYFRA21-1 in diagnosing MPE was 17.35, indicating the significantly increased diagnostic accuracy of MPE.

The diagnosis of MPE is currently based on finding tumor cells in PE or tissue. However, whether tumor cells are detected in PE or not depends on the pathologist’s experience, tumor histologic type, and degree of pleural invasiveness [30]. Although thoracoscopy can diagnose about 90% of PE cases, this method is not always feasible, especially in patients with advanced disease and unstable clinical conditions. Therefore, the limited sensitivity of PE cytology has forced us to seek new auxiliary diagnostic methods to improve the reliability of diagnoses, especially in cytology-negative cases. Hsieh et al. evaluated the diagnostic value of HER2/neu, CYFRA21-1, and CEA to distinguish LAC-associated cytologically negative PE (LAC-CNPES) from BPEs [28], but the sensitivities of the three markers were poor [28]. However, the combination of CEA and CYFRA21-1 increased the sensitivity to 66.7%. Another study conducted by Antonangelo et al. indicated that PE CA125 might be used to distinguish cytology-negative MPE from BPE [7]. Therefore, we evaluated the diagnostic value of tumor markers in distinguishing cytology-negative MPE from BPE. Our results indicated that the combination of PE CEA and serum CYFRA21-1 showed a better diagnostic performance in distinguishing cytology-negative MPE from BPE with an AUC of 0.834 than single PE CEA or serum CYFRA21-1. The sensitivity, specificity, PPV, and PLR were 67.7%, 91.0%, 61.5%, and 9.55, respectively. Previously, we also developed and validated a scoring system based on a nomogram for distinguishing MPE and BPE, which performed well for differentiating lung cancer and tuberculosis [31]. However, the diagnosis of MPE was according to the presence of malignant cells in PE cytology in our previous study [31]. At present, many clinicians still regard positive cytology as the gold standard for MPE diagnosis, but the accuracy rate of this method is only
Carried out to validate our multicenter studies with different populations should be a single-center retrospective study. More prospective and comprehensive investigation of MPE, which is beneficial to improve the diagnostic accuracy for patients with MPE. The patients used in our two articles were overlapped.

The reasons for the overlapping patient cohort were mainly due to the differences in the analyzed variables, the statistical time, and whether mesothelioma and hematologic tumors were excluded or not. In general, our results might be useful in the complementary diagnosis of MPE when cytology is suspected or negative, avoiding more invasive procedures in clinical practice. Besides, the detection of two tumor markers is convenient and can be detected in most hospitals, which is beneficial for early clinical decision making.

To the best of our knowledge, the sample size of our study was the largest, and various types of tumors were included in our study. Besides, the sample sizes of previously reported studies included no more than 300 individuals, and many studies were about lung cancer-associated PE, which may lead to statistical bias. Moreover, the tumor markers in PE, serum, and their corresponding ratio in our study were comprehensively investigated in distinguishing MPE from BPE. We also used a combination of two or more indicators to diagnose MPE, especially in cytology-negative MPE. Therefore, our study will provide an early and accurate reference for the auxiliary diagnosis of MPE, which might be useful in the clinical decision making.

However, our study has several limitations. First, the study was a single-center retrospective study. More prospective and multicenter studies with different populations should be carried out to validate our findings. Second, we did not compare the diagnostic value of tumor markers in discriminating LAC-MPE from other causes of MPE, though LAC-MPE accounted for the majority of MPE sources in clinical practice. Therefore, further studies should focus on discriminating LAC-MPE from other causes of MPE. Third, the diagnostic sensitivity for MPE in our study was not high. We were unable to combine the markers with thoracoscopy or imaging examination for MPE diagnosis due to unavailable data.

In summary, PE CEA at a cut-off value of 3.7 ng/ml showed the best diagnostic performance in distinguishing MPE from BPE. PE CEA and serum CYFRA21-1 were effective diagnostic tumor markers in distinguishing cytology-negative MPE from BPE. Combinations of PE CEA and serum CYFRA21-1 could increase the diagnostic accuracy in distinguishing MPE from BPE and cytology-negative MPE from BPE.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethics Committee of Ningbo First Hospital. The Ethics Committee waived the requirement of written informed consent for participation.

**AUTHOR CONTRIBUTIONS**

YL and AW designed the study and revised the manuscript. XF analyzed the data and XF wrote the primary manuscript. ZL, SW, and JY collected the clinical data. All authors reviewed and approved the final manuscript.

**FUNDING**

The study was supported by the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (Grant number: 2022KY308).

**CONFLICT OF INTEREST**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**ACKNOWLEDGMENTS**

We thank Dr. Chao Cao for his guidance and assistance in the study.

**REFERENCES**

1. Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, et al. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med (2018) 198(7): 839–49. doi:10.1164/rccm.201807-1415ST

2. Wang S, Tian S, Li Y, Zhan N, Guo Y, Liu Y, et al. Development and Validation of a Novel Scoring System Developed from a Nomogram to Identify Malignant Pleural Effusion. EBioMedicine (2020) 58:102924. doi:10.1016/j.ebiom.2020.102924

3. Shafiq M, Feller-Kopman D. Management of Malignant Pleural Effusions. Clin Chest Med (2020) 41(2):259–67. doi:10.1016/j.ccm.2020.02.009

4. Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of Pleural Effusions: Analysis of More Than 3,000 Consecutive Thoracenteses. Archivos de Bronconeumología (English Edition) (2014) 50(5):161–5. doi:10.1016/j.arbres.2013.11.007

5. Arnold DT, De Fonseka D, Perry S, Morley A, Harvey JE, Medford A, et al. Investigating Unilateral Pleural Effusions: the Role of Cytology. Eur Respir J (2018) 52(5):1801254. doi:10.1183/13993003.01254-2018

6. Maturu VN, Dhoooria S, Bal A, Singh N, Aggarwal AN, Gupta D, et al. Role of Medical Thoracoscopy and Closed-Blind Pleural Biopsy in Undiagnosed...
Exudative Pleural Effusions. J Bronchology Interv Pulmonol (2015) 22(2): 121–9. doi:10.1097/lbr.0000000000000145

7. Antonangelo L, Sales RK, Corá AP, Accenio MMP, Teixeira LR, Vargas FS. Pleural Fluid Tumor Markers in Malignant Pleural Effusion with Inconclusive Cytologic Results. *Curr Oncol* (2015) 22(5):336–41. doi:10.3747/co.22.2563

8. Nguyen AH, Miller EJ, Wichman CS, Berim IG, Agrawal DK. Diagnostic Value of Tumor Antigens in Malignant Pleural Effusion: a Meta-Analysis. *Translational Res* (2015) 166(5):432–9. doi:10.1016/j.trsl.2015.04.006

9. Yang Y, Liu Y-L, Shi H-Z. Diagnostic Accuracy of Combinations of Tumor Markers for Malignant Pleural Effusion: An Updated Meta-Analysis. *Respiration* (2017) 94(1):62–9. doi:10.1159/000468545

10. Huang W-W, Tsao S-M, Lai C-L, Su C-C, Tseng C-E. Diagnostic Value of Her-2/neu, Cyfra 21-1, and Carcinoembryonic Antigen Levels in Malignant Pleural Effusions of Lung Adenocarcinoma. *Pathology* (2010) 42(3):224–8. doi:10.3109/003130120103631320

11. Son S-M, Han H-S, An JY, Cho KH, Lee KM, Lee KH, et al. Diagnostic Performance of CD66c in Lung Adenocarcinoma-Associated Malignant Pleural Effusion: Comparison with CEA, CA 19-9, and CYFRA 21-1. *Pathology* (2015) 47(2):123–9. doi:10.1097/path.0000000000000215

12. Feng M, Zhu J, Liang L, Zeng N, Wu Y, Wan C, et al. Diagnostic Value of Tumor Markers for Lung Adenocarcinoma-Associated Malignant Pleural Effusion: a Validation Study and Meta-Analysis. *Int J Clin Oncol* (2017) 22(2):283–90. doi:10.1186/s10477-016-1073-y

13. Zhang H, Li C, Hu F, Zhang X, Shen Y, Chen Y, et al. Auxiliary Diagnostic Value of Tumor Biomarkers in Pleural Fluid for Lung-Cancer-Associated Malignant Pleural Effusion. *Respir Res* (2020) 21(1):284. doi:10.1186/s12931-020-01557-z

14. Paganuzzi M, Onetto M, Marroni P, Fàlberti R, Tassara E, Parodi S, et al. Diagnostic Value of CYFRA 21-1 Tumor Marker and CEA in Pleural Effusion Due to Mesothelioma. *Chest* (2001) 119(4):1138–42. doi:10.1378/chest.119.4.1138

15. Villena V, López-Ercuentra A, Echave-Sustaita J, Martínez-Escribano P, Ortiz-Peñalver B, Estenoz-Alfaro J. Diagnostic Value of CA 549 in Pleural Fluid. Comparison with CEA, CA 15.3 and CA 72.4. *Cancer* (2003) 40(3):289–94. doi:10.1016/S0169-5002(03)00120-X

16. Hackbart JS, Murata K, Reilly WM, Algeciras-Schimnich A. Performance of CEA and CA19-9 in Identifying Pleural Effusions Caused by Specific Malignancies. *Clin Biochem* (2010) 43(13-14):1051–5. doi:10.1016/j.clinbiochem.2010.03.016

17. Filiberti R, Parodi S, Libener R, Ivaldi GP, Canessa PA, Ugolini D, et al. Diagnostic Value of Mesothelin in Pleural Fluids: Comparison with CYFRA 21-1 and CEA. *Med Oncol* (2013) 30(2):543. doi:10.1007/s12032-013-0543-6

18. Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F. Use of a Panel of Tumor Markers (Carcinoembryonic Antigen, Cancer Antigen 125, Carbohydrate Antigen 15-3, and Cytokeratin 19 Fragments) in Pleural Fluid for the Differential Diagnosis of Benign and Malignant Effusions. *Chest* (2004) 126(6):1757–63. doi:10.1378/chest.126.6.1757

19. Shirit D, Zingerman B, Shirit AB-G, Shlomi D, Kramer MR. Diagnostic Value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 Assays in Pleural Effusions: Analysis of 116 Cases and Review of the Literature. *Oncologist* (2005) 10(7):501–7. doi:10.1634/thoracicologist.10-7-501

20. Gaspar MJ, De Miguel J, García Díaz JD, Díez M. Clinical Utility of a Combination of Tumour Markers in the Diagnosis of Malignant Pleural Effusions. *Anticancer Res* (2008) 28(5b):2947–52.

21. Zhai K, Wang W, Wang Y, Liu J-Y, Zhou Q, Shi H-Z. Diagnostic Accuracy of Tumor Markers for Malignant Pleural Effusion: a Derivation and Validation Study. *J Thorac Dis* (2017) 9(12):5220–9. doi:10.21037/jtd.2017.11.62

22. Volarić D, Flego V, Zauhar G, Bulat-Kardum L. Diagnostic Value of Tumor Markers in Pleural Effusions. *Biochem Med (Zagreb)* (2018) 28(1):010706. doi:10.11613/bmm.2018.010706

23. Grunnet M, Sorensen JB. Carcinoembryonic Antigen (CEA) as Tumor Marker in Lung Cancer. *Lung Cancer* (2012) 76(2):138–43. doi:10.1016/j.lungcan.2011.11.012

24. Tozzoli R, Basso SMM, D’Aurizio F, Metus P, Lumachi F. Evaluation of Predictive Value of Pleural CEA in Patients with Pleural Effusions and Histological Findings: A Prospective Study and Literature Review. *Clin Biochem* (2016) 49(16-17):1227–31. doi:10.1016/j.clinbiochem.2016.08.006

25. Rodríguez-Panadero F, Borderas Naranjo F, López Mejías J. Pleural Metastatic Tumours and Effusions. Frequency and Pathogenic Mechanisms in a post-mortem Series. *Eur Respir J* (1989) 2(4):366–9.

26. Chen Z, Wang Y, Fang M. Analysis of Tumor Markers in Pleural Effusion and Serum to Verify the Correlations between Serum Tumor Markers and Tumor Size, TNM Stage of Lung Adenocarcinoma. *Cancer Med* (2020) 9(4):1392–9. doi:10.1002/cam4.2809

27. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant Pleural Effusion: from Bench to Bedside. *Eur Respir Rev* (2016) 25(140):189–98. doi:10.1183/16000617.0019-2016

28. Hsieh T-C, Huang W-W, Lai C-L, Tsao S-M, Su C-C. Diagnostic Value of Tumor Markers in Lung Adenocarcinoma-Associated Cytologically Negative Malignant Pleural Effusions. *Cancer Cytopathology* (2013) 121(9):483–8. doi:10.1002/cncy.21283

29. Wang TX, Hu D, Yan X. Diagnostic Accuracy of Cyfra 21-1 for Head and Neck Squamous Cell Carcinoma: a Meta-Analysis. *Eur Rev Med Pharmacol Sci* (2013) 17(17):2383–9.

30. Hooper C, Lee YCG, Maskell N. Investigation of a Unilateral Pleural Effusion in Adults: British Thoracic Society Pleural Disease Guideline 2010. *Thorax* (2010) 65(Suppl. 2):iii4–ii17. doi:10.1136/thx.2010.136978

31. Wu A, Liang Z, Yuan S, Wang S, Peng W, Mo Y, et al. Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram. *Front Oncol* (2021) 11:775079. doi:10.3389/fonc.2021.775079

Copyright © 2022 Fan, Liu, Liang, Wang, Yang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.